Baird Upgrades DaVita HealthCare To Outperform

Analysts at Baird upgraded

from Neutral to Outperform. The price target for DaVita HealthCare has been raised from $75.00 to $95.00. DaVita HealthCare shares have gained 21.19 percent over the past 52 weeks, while the S&P 500 index has surged 13.28 percent in the same period. DaVita HealthCare shares rose 0.60 percent to close at $83.91 on Friday.